-
1.发明公开公开(公告)号：US20240216421A1
公开(公告)日：2024-07-04
申请号：US18557471
申请日：2022-04-26
申请人： DIOTHERIS , UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
IPC分类号： A61K31/74 , A61K31/351 , A61K31/496 , A61K31/665 , A61P31/04
CPC分类号： A61K31/74 , A61K31/351 , A61K31/496 , A61K31/665 , A61P31/04
摘要： The present invention relates to a combination product comprising an antibiotic and at least one non-pathogenic microorganism for simultaneous, separate, or sequential use in preventing emergence of resistance to the antibiotic when treating a colonization and/or an infection caused by a bacterium that is susceptible to said antibiotic, wherein said at least one non-pathogenic microorganism is resistant to said antibiotic.
-
公开(公告)号：US20230134548A1
公开(公告)日：2023-05-04
申请号：US17866022
申请日：2022-07-15
IPC分类号： C12N15/113 , A61P13/06 , A61K38/16 , A61K38/17 , A61K38/45 , A61K38/48 , A61K38/51 , C12N15/86
摘要： The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.
-
公开(公告)号：US10364430B2
公开(公告)日：2019-07-30
申请号：US14164880
申请日：2014-01-27
申请人： Institut Gustave-Roussy , INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE SCIENTIFIQUE MEDICALE (INSERM) , ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS , UNIVERSITE DE VERSAILLES—ST QUENTIN EN YVELINES , UNIVERSITE PARIS-SUD
IPC分类号： C12N9/12 , C12N15/113 , C12Q1/6813 , C12Q1/6883 , G01N33/574
摘要： The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
-
公开(公告)号：US20190167734A1
公开(公告)日：2019-06-06
申请号：US16270296
申请日：2019-02-07
发明人： Jean-Louis GAILLARD , Didier GUILLEMOT , Jean-Louis HERRMANN , Martin ROTTMAN , Anne-Sophie ALVAREZ , Jérôme SALOMON , Valérie LESELLIER
摘要： The present invention relates to a pharmaceutical composition comprising at least one Corynebacterium sp, Staphylococcus pasteuri and, optionally, Staphyloccocus epidermidis for use as a medicament, in particular for use in the prevention or treatment of S. aureus colonization.
-
公开(公告)号：US20240042002A1
公开(公告)日：2024-02-08
申请号：US17789451
申请日：2020-12-31
申请人： ANTAGONIS , UNIVERSITE DE VERSAILLES-ST QUENTIN EN YVELINES , ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
IPC分类号： A61K39/085 , A61K39/40 , A61P31/04 , G01N33/569 , C12Q1/18
CPC分类号： A61K39/085 , A61K39/40 , A61P31/04 , G01N33/56938 , C12Q1/18 , G01N2333/31 , G01N2469/10
摘要： The present invention relates to an immunogenic composition comprising at least one Staphylococcus aureus antigen, wherein said antigen is a polypeptide having at least 80% identity with the SdrH-like polypeptide of SEQ ID NO: 8, Nuc of SEQ ID
NO: 4, or LukG of SEQ ID NO: 12, an immunotherapeutic composition comprising a polyclonal antibody which selectively binds to at least one of said antigens, and an in vitro method of identifying an antigen conferring protection against disease caused by S. aureus in a subject.-
公开(公告)号：US11723956B2
公开(公告)日：2023-08-15
申请号：US16327543
申请日：2017-08-31
申请人： Institut National de la Sante et de la Recherche Medicale (INSERM) , Centre National de la Recherche Scientifique (CNRS) , UNIVERSITÉ DE PARIS , Assistance Publique—Hopitaux de Paris , Ecole Nationale Superieure de Chimie de Paris , Universite de Versailles—St Quentin en Yvelines
发明人： Robert Malafosse , Nathalie Mignet , Vincent Boudy , Johanne Seguin , Kathia Lemdani , Claude Capron
IPC分类号： A61K38/19 , A61K39/07 , A61K41/00 , A61K47/10 , A61K47/36 , A61P35/00 , A61K47/34 , A61K9/00 , A61K39/04 , A61K9/06 , C07K16/28 , A61K31/765 , A61K39/395 , A61K38/38 , A61K39/00
CPC分类号： A61K38/193 , A61K9/0019 , A61K9/0024 , A61K9/06 , A61K31/765 , A61K38/385 , A61K39/04 , A61K39/07 , A61K39/39541 , A61K41/0028 , A61K41/0052 , A61K47/10 , A61K47/34 , A61K47/36 , A61P35/00 , C07K16/2818 , A61K2039/505 , A61K2039/522 , A61K2039/54 , A61K2039/55522 , A61K2039/585 , A61K2039/82 , C07K2317/76 , A61K39/39541 , A61K2300/00
摘要： The present invention concerns a thermosensitive polymeric hydrogel comprising at least one thermosensitive copolymer, one aqueous solution, and a mucoadhesive excipient, wherein said thermosensitive polymeric hydrogel further comprises at least one immunostimulatory adjuvant and/or at least one cytokine and/or at least one chemokine and/or atleast one heat shockprotein. Another object of the invention is a thermosensitive polymeric hydrogel according to the invention for use in the treatment of tumors or metastasis in a subject having a cancer, preferably a metastatic cancer.
-
公开(公告)号：US10563200B2
公开(公告)日：2020-02-18
申请号：US16424976
申请日：2019-05-29
申请人： Institut Gustave-Roussy , Institut National de la Sante et de la Rescherche Medicale (INSERM) , Assistance Publique—Hopitaux de Paris , Universite de Versailles—St Quentin en Yvelines , Universite Paris—Sud
IPC分类号： C12N15/113 , G01N33/574 , C12Q1/6883 , C12Q1/6813 , C12N9/12
摘要： The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
-
8.发明申请公开(公告)号：US20190392612A1
公开(公告)日：2019-12-26
申请号：US16431237
申请日：2019-06-04
申请人： Centre National de la Recherche Scientifique (CNRS) , Universite Paris Descartes , Ecole Nationale Superieure de Chimie de Paris , Assistance Publique-Hopitaux de Paris , Universite De Versailles-St Quentin En Yvelines , Institut National de la Sante et de la Recherche Medicale (INSERM)
发明人： Kathia Lemdani , Johanne Seguin , Armand Tiede Djiro , Jean-Francois Emile , Camille Kurtz , Nicolas Lomenie
摘要： The invention relates to a process for determining an infiltration profile of biological cells of interest in a biological object of interest from a digital histopathological image of biological tissues, a histological stain having previously been applied to the biological tissues, comprising generating a biological cell detection image, pixels associated with the histological stain on the histopathological image being of a predetermined color on said image, determining a distance map comprising distance iso-curves to the boundary of the biological object, and, from the distance map, calculating a curve representative of the surface density of biological cells of interest as a function of distance to the boundary, by counting, for each boundary distance value, pixels that are both of the predetermined color on the detection image and located between the iso-curve associated with said distance value and the consecutive iso-curve.
-
公开(公告)号：US20140249204A1
公开(公告)日：2014-09-04
申请号：US14164880
申请日：2014-01-27
申请人： Institut Gustave-Roussy , Institut National De La Sante Et De La Rechereche Scientifique (Inserm) , Universite Paris-Sud , Universite De Versailles - St Quentin En Yvelines , Assistance Publique-Hopitaux De Paris
IPC分类号： C12Q1/68 , C12N15/113
CPC分类号： C12Q1/6813 , C12N9/1205 , C12N15/113 , C12Q1/6883 , C12Q2600/156 , G01N33/57426 , G01N33/57496 , G01N2333/91215 , G01N2500/04
摘要： The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group.
摘要翻译： 本发明涉及蛋白质 - 酪氨酸激酶JAK2的V617F变体，所述变体负责Vaquez Polyglobulia。 本发明还涉及允许其与骨髓增生性疾病相关的红细胞增多症和血小板增多症的第一意图诊断方法，或用于检测骨髓增生性疾病中的JAK2 V617F变体，从而允许其在新的神经学组中重新分类。
-
公开(公告)号：US20240229044A9
公开(公告)日：2024-07-11
申请号：US18534884
申请日：2023-12-11
IPC分类号： C12N15/113 , A61K38/16 , A61K38/17 , A61K38/45 , A61K38/48 , A61K38/51 , A61P13/06 , C12N15/86
CPC分类号： C12N15/1138 , A61K38/164 , A61K38/1793 , A61K38/45 , A61K38/4893 , A61K38/51 , A61P13/06 , C12N15/86 , C12Y304/24069 , C12Y401/01015 , C12N2310/11 , C12N2320/31 , C12N2320/32 , C12N2710/16643 , C12N2830/008 , C12N2830/40
摘要： The present invention provides a method and a pharmaceutical composition for the treatment of the NDO comprising the viral expression vector carrying a transcription cassette that harbors transgene(s) inhibiting/silencing neurotransmission or synaptic transmission of afferent neurons.
-
-
-
-
-
-
-
-
-
搜索结果
22 条记录 (耗时 0.023 秒)
